
NeuroD1 and Ascl1 Convert Human Glial Cells into Neurons in Ex Vivo Culture of Human Brain Tissue
Brief intro:
- Author: Liang Xu, Qingsong Wang, Jiancheng Liao, Jiajun Zheng, Bing Qin, Wen Li, Jiaxuan Zhang, Wei Li, Xiangyu Wang, Maoying Zhang, Gong Chen
- Journal: Research Square
- Doi: https://www.doi.org/10.21203/rs.3.rs-3697467/v1
- Publication Date: 2023 Dec 14
Products/Services used in the paper
Quotation shows PackGene:Adeno-associated virus (AAV): AAV9 GFAP::Cre, AAV9 CAG::Flex-GFP and AAV9 CAG::Flex-NeuroD1-GFP were produced by PackGene Biotech (Guangzhou, China)
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:HEK293T
Abstract
Transcription factor-mediated cell conversion has been reported in the central nervous system (CNS) of both rodents and non-human primates (NHPs). In particular, glia-to-neuron (GtN) conversion has been achieved in the brains and spinal cords of animal models of neurological disorders for neural regeneration and repair. However, whether GtN conversion can ultimately be used for human brain repair in patients is still unknown. To investigate the applicability of GtN conversion technology in the human brain, we established a long-term ex vivo culture system using human brain tissue that was surgically removed from epileptic patients to directly test GtN conversion. We demonstrate that both neural transcription factors NeuroD1 and Ascl1 can convert human glial cells into neurons. Importantly, both immunostaining and electrophysiological recordings revealed that the glia-converted neurons showed immature properties during the initial 1–2 weeks of conversion, and then acquired more mature neuronal properties after 3–4 weeks of conversion. These ex vivo conversion studies in human brain tissue pave the way toward future clinical trials using a transcription factor-based glia-to-neuron conversion approach to treat neurological disorders.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
